The idea is to make mySugr an integral part of Roche's new patient-centered digital health services platform in diabetes care.
The company will use the funds to expand to other chronic conditions, and move to international markets.
Under the deal, the Livongo for Diabetes program will be offered with Voluntis' Insulia, an FDA-cleared medical device and app.
Users will benefit from enhanced capabilities to share diabetes data with their healthcare providers and caregivers.
The company will use the money to continue development of Glyde, a long-term injectable glucose sensor.
Now, members will have access to Solera's nationwide network of Diabetes Prevention Programs (DPP) as a covered medical benefit.
Ascensia Diabetes Care and Glooko teamed-up to bring together their state-of-the-art diabetes management solutions.
The money will be used to further develop Bigfoot's automated insulin delivery service called smartloop.
The program will combine insulin dosing data, real-time blood glucose data, and data from Welkin Health coaches to support patients in their daily lives.
The non-prescription version will have all the first-in-class features of BlueStar® Rx apart from an insulin calculator.